Since CCR4- effector T cells are barely present at the tumor site, the forced co-expression of surface CCR4 in CAR-T cells appears to be a promising therapeutic strategy in the treatment of certain types of lymphomas. This evidence concerns the gene CCR4 and lymphoma.